Drug intelligence / Profile preview

Inhapro

Development stage: Preclinical
Lead developer: Adamed Pharma
Administration: Inhalation, Intravenous

Overview

Inhapro is a first-in-class biologic being developed by Adamed Pharma for the treatment of non-small cell lung cancer (NSCLC) and severe pulmonary or immuno-inflammatory lung diseases. It operates through a novel, undisclosed mechanism of action. The drug is designed for both systemic and inhaled administration, allowing for direct delivery to the respiratory system or broader systemic effects. As of 2024, the program is in the preclinical stage of development, targeting high-unmet-need conditions in oncology and pulmonology.

Beyond the preview

Go deeper on Inhapro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhapro.

Explore the full profile